Study Shows Ketosis Fights Alzheimer's Disease

Ketosis Strips

An increasing number of studies report that interventions to enhance metabolic health can
alleviate symptoms and reduce brain pathology associated with AD.

PALM BEACH GARDENS, FL, UNITED STATES, January 31, 2018 /EINPresswire.com/ — Despite decades of attempts to develop a medication that cures or prevents Alzheimer's
disease (AD), the most common form of dementia afflicting our aging population, there's
presently no cure for this devastating illness. Emerging research indicates that such a miracle
remedy might already exist, maybe not in the kind of a pill, but as a straightforward dietary
modification. People can check for ketones by using ketosis strips. They are inexpensive and
can be found at the local pharmacy or online at KetoStrips.com.

An increasing number of studies report that interventions to enhance metabolic health can
alleviate symptoms and reduce brain pathology associated with AD. A favorite theory posits
that AD has numerous causes, but their common thread can demand metabolic breakdown.
Indeed, markers of poor metabolic health, like diabetes, inflammation and higher cholesterol,
are significant risk factors for AD.

The same as our muscles, the brain requires energy to function properly. Both neurons and
muscles have the unique capability to metabolize ketones as an alternative fuel source when
sugar is in short supply, for example through fasting or on a low-carbohydrate diet. In the
1920s scientists discovered a high-fat diet boosting ketogenesis controlled epilepsy. Also
ketosis is still one of the very best treatments for the condition. This increased the possibility
that ketones may also be neuroprotective against other diseases that stem from aberrant
neural metabolism, such as AD. Since then, research has confirmed that ketones do in fact
alter brain metabolism in ways that decrease neuropathology and relieve behavioral signs.
People can check for ketones by using ketosis strips. They are inexpensive and can be found
at the local pharmacy or online at KetoStrips.com

Ketones relieve symptoms of Alzheimer's disease

Over the last ten years, several studies have affirmed the clinical value of ketosis in cognitively
impaired patients. At a 2004 study, twenty people with AD or Mild Cognitive Impairment (MCI)
were treated with placebo or medium chain triglycerides, a sort of saturated fat found in
coconut and palm oils that boosts ketone production. The treatment increased ketone levels 90
minutes afterward, and these higher ketone levels corresponded with increased memory
improvements. All these preliminary, short-term findings were followed up five years later in a
bigger and longer-term study of 152 mild AD patients. After 45 days, individuals taking a
ketogenic chemical showed cognitive enhancements relative to a placebo group. But, both
these studies imply that the brain benefits of ketosis may depend on genetics. In the prior
study, medium chain triglycerides improved cognitive functioning only in participants with no
ApoE4 allele, a genetic risk factor for AD. Similarly, in the later study, cognitive improvements
had been more powerful and persisted longer–outside to 90 days–in those without the ApoE4
allele. A new PLOS One analysis confirmed different answers to diet based on genetics in
mice, reporting a high-fat diet lowered brain levels of ApoE only in mice with no ApoE4 gene.

These promising early findings of ketogenic compounds provided hope that dietary
interventions might similarly benefit brain health. A 2012 study tested whether memory could
be improved by simply adopting a low-carbohydrate diet, without the necessity of supplements
used in the prior studies. Of 23 people with MCI, those after an extremely low-carbohydrate
diet for six months showed improved memory in contrast to people on a high-carbohydrate
diet. These memory enhancements correlated with ketone levels, but maybe not with carbs
consumed, insulin levels or body fat, pointing to increased ketogenesis because the probable
reason behind its low carb dieters' cognitive enhancement.

Although ketosis hasn't been rigorously tested in a proper clinical trial, a recent case study
provides compelling proof that ketones might, in fact, hold up in acute clinical cases. A 63-yearold
guy with advanced AD started consuming coconut oil and medium chain triglycerides, both
proven to increase ketone levels. After just 2.5 months, his score on the Mini-Mental State
Exam, a test of global cognitive functioning, improved from a very low 12 to 20 (from a
maximum 30). After two years, his cognitive capacity and daily living functions both improved
and his MRI revealed no additional brain atrophy. After adding a ketone ester supplement to
his dietary regimen, the patient revealed even further improvements in his disposition, selfsufficiency,
and memory. Notably, this man completed the ApoE4 gene; thus, ketosis does
appear to be extremely beneficial for ApoE4 carriers, even if previous studies suggest it's even
more helpful for those without this risk factor.

How ketones protect the brain

Scientists have looked to animal models to better understand how ketosis may protect the
human brain from neurodegeneration. In a mouse model of AD, amounts of beta-amyloid, a
toxic protein that is elevated in AD, were decreased in the brains of mice fed a high-fat/lowcarb
diet compared to those on a standard diet. Latest research helped to clarify the
connection between the metabolic benefits of ketones, lower amyloid, and improved cognitive
functioning. This study tested the effects ketones either in a mouse model of AD and neurons
treated with amyloid. What's more, ketones decreased amyloid levels and obstructed the
formation of pores in cell membranes induced by amyloid, showing that ketones can protect
against cerebral damage linked to amyloid. At length, ketones revived normal synaptic
plasticity and memory performance which were impaired by amyloid.

A prescription for Ketosis

If ketosis would be to become confirmed as an effective treatment for AD, further study is
needed to determine the appropriate method of administration, since high-fat diets, medium
chain triglyceride supplements or ketogenic substances might be differentially effective. Patient
compliance in following a strict diet or taking supplements may also pose potential challenges.
Identifying the minimum effective dose will help establish guidelines for how rigorous a
treatment regimen is necessary. Despite these remaining questions, the compelling support for
the healing potential of ketosis provides hope that a powerful weapon in our struggle against
AD may already exist–and can be as delicious as a spoonful of coconut oil.

Read More

Everett Wilkinson
KetoStrips.com
5618808805
email us here


Source: EIN Presswire

Adaptive Computing Enterprises Launches New Product for HPC Cloud Bursting

Moab/NODUS Cloud Bursting for HPC enables seamless access to all leading cloud providers.

The Moab/NODUS Cloud Bursting Solution is brilliant in its ability to integrate seamlessly with existing management infrastructure.”

— Art Allen, President, Adaptive Computing Enterprises, Inc.

NAPLES, FLORIDA, USA, January 31, 2018 /EINPresswire.com/ — Adaptive Computing announces its new Cloud Solution, Moab/NODUS Cloud Bursting, making HPC cloud strategies more accessible than ever before.

“Considering that public cloud bursting is usually extremely challenging, the Moab/NODUS Cloud Bursting Solution is brilliant in its ability to integrate seamlessly with existing management infrastructure,” said Art Allen, President, Adaptive Computing Enterprises, Inc.

Adaptive’s product Moab, already a world leader in dynamically optimizing large-scale HPC computing environments, has been enhanced to extend running HPC workloads into public clouds. Adaptive’s engineering team has done a fantastic job of making clouds work for HPC. The Moab/NODUS Cloud Bursting Solution is powerful, flexible, easy to implement, and manage. From the automated deployment and release of nodes, to the ease of use for admins, Moab/NODUS Cloud Bursting makes access to multiple public clouds easily attainable.

The Moab/NODUS Cloud Bursting Solution provides Infrastructure and Operations leaders the ability to achieve substantial cost savings by reducing on-premise infrastructure refresh costs; by meeting SLA’s, thereby avoiding financial penalties; and by increasing revenue by speeding up time to market for various use cases.

Adaptive Computing Enterprises was acquired in September 2016 by Arthur L. Allen, long-time software industry veteran with more than 40 years creating software companies and technology solutions. Adaptive Computing has been totally transformed into a new, innovative company.

“While we will continue to be price competitive, Adaptive Computing will lead with product innovation, product quality, and extraordinary customer support,” Allen said. “The company is striving to be the thought leader in the HPC and Data Center spaces. The first of such solutions is Moab/NODUS Cloud Bursting.”

About Adaptive Computing

Adaptive Computing's Workload and Resource Orchestration software platform, Moab, is a world leader in dynamically optimizing large-scale computing environments. Moab intelligently places and schedules workloads and adapts resources to optimize application performance, increase system utilization, and achieve organizational objectives. Moab's unique intelligent and predictive capabilities evaluate the impact of future orchestration decisions across diverse workload domains (HPC, HTC, Big Data, Grid Computing, SOA, Data Centers, Cloud Brokerage, Workload Management, Enterprise Automation, Workflow Management, Server Consolidation, and Cloud Bursting); thereby optimizing cost reduction and speeding product delivery. Moab gives enterprises a competitive advantage, inspiring them to develop cancer-curing treatments, discover the origins of the universe, lower energy prices, manufacture better products, improve the economic landscape, and pursue game-changing endeavors.

Sue DeGram
Adaptive Computing Enterprises Inc.
2393306123
email us here

Moab/NODUS Cloud Bursting


Source: EIN Presswire

Global Gene Therapy Market Expected to Reach $4,300 Million by 2021: Polaris Market Research

The Rising demand of the personalized treatments and need for the one stop cure for the rare indications and niche segments of the disease has led to the emergence of the gene therapies.”

— Polaris Market Research

BROOKLYN, NY, UNITED STATES, January 31, 2018 /EINPresswire.com/ — The Global Gene Therapy market size is expected to reach USD 4,300 million market by 2021 as reported by Polaris Market Research.

The Rising demand of the personalized treatments and need for the one stop cure for the rare indications and niche segments of the disease has led to the emergence of the gene therapies as a therapy option for the critical and deadly indications. The positive attitude of regulatory bodies has also created a favorable environment for the research and development in these therapies.

As of January 2018, there are 3000+ Reported Clinical Trials for Gene therapies, out of which 500+ trials are currently ongoing. The increase in the government funds for the research and development also paving the way for the secure future of gene therapies in coming time.

Polaris Market Research expects that with the expected launch of the potential gene therapies, the market is expected to rise at a higher pace. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is subjected to the approval of KYMRIAH (Novartis), YESCARTA (Kite Pharmaceuticals) and LUXTURNA (Spark Therapeutics) and associated premium pricing.

Currently the Gene Therapy market is highly fragmented but with the current initiatives taken by the government and fastened approval process in developed countries, the market is soon going to be regulated.

The only restrain to the Gene Therapy market is premium pricing of the therapies. Polaris Market Research believes that the affordability of gene therapy is one of the primary concern in the mature markets. GlaxoSmithKline recently in October 2017 launched the gene therapy, STRIMVELIS for the ultra-rare disorder i.e. Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency (AD-SCID) This drug comes with the price tag of $665,000 which makes it THE expensive drug in the entire gene therapy segment. The drug also comes with money back guarantee as reported by the company itself.

Polaris Market Research has provided the forecasts of the Global Gene Therapy Market from 2016-2021.

The major segments which has been investigated in the global market from 2016-2021 are:

1. Market Analysis by Marketed Gene Therapies
2. Market Analysis by Companies
3. Market Analysis by Indications

The Marketed Therapies undertaken in forecast from 2016-2021 are:

1. Rexin-G (Epeius Biotechnologies Corporation)
2. Gendicine (SiBiono GeneTech Co., Ltd)
3. Neovasculgen [Human Stem Cells Institute (HSCI))
4. Glybera (UniQure Biopharma B.V.)
5. KYMRIAH (Novartis)
6. YESCARTA (Kite Pharmaceuticals)
7. LUXTURNA (Spark Therapeutics)
8. STRIMVELIS (GlaxoSmithKline)

The Major Indications in Gene Therapy are:
1. Cancer
2. Neurodegenerative Disorders
3. Lysosomal Storage Disorders (LSDs)
4. Ocular Diseases
5. Muscle Disorders
6. Anemia
7. Hemophilia
8. Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency

Leading Companies investigated in the Report are

1. Novartis Pharmaceuticals Corporation
2. Kite Pharma, Incorporated
3. Spark Therapeutics, Inc
4. GlaxoSmithKline
5. Adaptimmune
6. Bluebird bio
7. Celgene
8. Shanghai Sunway Biotech
9. Shenzhen SiBiono GeneTech
10. SynerGene Therapeutics
11. Others

Browse other reports by Polaris Market Research:
https://www.polarismarketresearch.com/industry/Healthcare/

Neel
Polaris Market Research & Consulting
+16465689980
email us here


Source: EIN Presswire

Global Bio-PET Film Market 2018 Industry Analysis, Size, Share, Growth, Trends, Opportunities and Forecast by 2022

WiseGuyReports.com adds “Bio-PET Film Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”reports to its database.

PUNE, INDIA, January 31, 2018 /EINPresswire.com/ — Bio-PET Film Market:

Executive Summary

This report studies Bio-PET Film in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering

Mondi Group
Toray
SKC Films
Polyplex
Uflex
M&G Chemicals
Teijssin Limited
Plastipak Holdings

Request Sample Report @ https://www.wiseguyreports.com/sample-request/2848635-global-bio-pet-film-market-professional-survey-report-2018

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Universal Film
Electrical Insulating Film
Capacitor Film
Laminating Film

By Application, the market can be split into

Packaging
Industrial & Specialties
Electrical
Imaging

By Regions, this report covers (we can add the regions/countries as you want)

North America
China
Europe
Southeast Asia
Japan
India

If you have any special requirements, please let us know and we will offer you the report as you want.

For further information on this report, visit – https://www.wiseguyreports.com/enquiry/2848635-global-bio-pet-film-market-professional-survey-report-2018

Table of content:

Global Bio-PET Film Market Professional Survey Report 2017 
1 Industry Overview of Bio-PET Film 
1.1 Definition and Specifications of Bio-PET Film 
1.1.1 Definition of Bio-PET Film 
1.1.2 Specifications of Bio-PET Film 
1.2 Classification of Bio-PET Film 
1.2.1 Universal Film 
1.2.2 Electrical Insulating Film 
1.2.3 Capacitor Film 
1.2.4 Laminating Film 
1.3 Applications of Bio-PET Film 
1.3.1 Packaging 
1.3.2 Industrial & Specialties 
1.3.3 Electrical 
1.3.4 Imaging 
1.4 Market Segment by Regions 
1.4.1 North America 
1.4.2 China 
1.4.3 Europe 
1.4.4 Southeast Asia 
1.4.5 Japan 
1.4.6 India

2 Manufacturing Cost Structure Analysis of Bio-PET Film 
2.1 Raw Material and Suppliers 
2.2 Manufacturing Cost Structure Analysis of Bio-PET Film 
2.3 Manufacturing Process Analysis of Bio-PET Film 
2.4 Industry Chain Structure of Bio-PET Film

3 Technical Data and Manufacturing Plants Analysis of Bio-PET Film 
3.1 Capacity and Commercial Production Date of Global Bio-PET Film Major Manufacturers in 2016 
3.2 Manufacturing Plants Distribution of Global Bio-PET Film Major Manufacturers in 2016 
3.3 R&D Status and Technology Source of Global Bio-PET Film Major Manufacturers in 2016 
3.4 Raw Materials Sources Analysis of Global Bio-PET Film Major Manufacturers in 2016

4 Global Bio-PET Film Overall Market Overview 
4.1 2012-2017E Overall Market Analysis 
4.2 Capacity Analysis 
4.2.1 2012-2017E Global Bio-PET Film Capacity and Growth Rate Analysis 
4.2.2 2016 Bio-PET Film Capacity Analysis (Company Segment) 
4.3 Sales Analysis 
4.3.1 2012-2017E Global Bio-PET Film Sales and Growth Rate Analysis 
4.3.2 2016 Bio-PET Film Sales Analysis (Company Segment) 
4.4 Sales Price Analysis 
4.4.1 2012-2017E Global Bio-PET Film Sales Price 
4.4.2 2016 Bio-PET Film Sales Price Analysis (Company Segment)

5 Bio-PET Film Regional Market Analysis 
5.1 North America Bio-PET Film Market Analysis 
5.1.1 North America Bio-PET Film Market Overview 
5.1.2 North America 2012-2017E Bio-PET Film Local Supply, Import, Export, Local Consumption Analysis 
5.1.3 North America 2012-2017E Bio-PET Film Sales Price Analysis 
5.1.4 North America 2016 Bio-PET Film Market Share Analysis 
5.2 China Bio-PET Film Market Analysis 
5.2.1 China Bio-PET Film Market Overview 
5.2.2 China 2012-2017E Bio-PET Film Local Supply, Import, Export, Local Consumption Analysis 
5.2.3 China 2012-2017E Bio-PET Film Sales Price Analysis 
5.2.4 China 2016 Bio-PET Film Market Share Analysis 
5.3 Europe Bio-PET Film Market Analysis 
5.3.1 Europe Bio-PET Film Market Overview 
5.3.2 Europe 2012-2017E Bio-PET Film Local Supply, Import, Export, Local Consumption Analysis 
5.3.3 Europe 2012-2017E Bio-PET Film Sales Price Analysis 
5.3.4 Europe 2016 Bio-PET Film Market Share Analysis 
5.4 Southeast Asia Bio-PET Film Market Analysis 
5.4.1 Southeast Asia Bio-PET Film Market Overview 
5.4.2 Southeast Asia 2012-2017E Bio-PET Film Local Supply, Import, Export, Local Consumption Analysis 
5.4.3 Southeast Asia 2012-2017E Bio-PET Film Sales Price Analysis 
5.4.4 Southeast Asia 2016 Bio-PET Film Market Share Analysis 
5.5 Japan Bio-PET Film Market Analysis 
5.5.1 Japan Bio-PET Film Market Overview 
5.5.2 Japan 2012-2017E Bio-PET Film Local Supply, Import, Export, Local Consumption Analysis 
5.5.3 Japan 2012-2017E Bio-PET Film Sales Price Analysis 
5.5.4 Japan 2016 Bio-PET Film Market Share Analysis 
5.6 India Bio-PET Film Market Analysis 
5.6.1 India Bio-PET Film Market Overview 
5.6.2 India 2012-2017E Bio-PET Film Local Supply, Import, Export, Local Consumption Analysis 
5.6.3 India 2012-2017E Bio-PET Film Sales Price Analysis 
5.6.4 India 2016 Bio-PET Film Market Share Analysis

6 Global 2012-2017E Bio-PET Film Segment Market Analysis (by Type) 
6.1 Global 2012-2017E Bio-PET Film Sales by Type 
6.2 Different Types of Bio-PET Film Product Interview Price Analysis 
6.3 Different Types of Bio-PET Film Product Driving Factors Analysis 
6.3.1 Universal Film of Bio-PET Film Growth Driving Factor Analysis 
6.3.2 Electrical Insulating Film of Bio-PET Film Growth Driving Factor Analysis 
6.3.3 Capacitor Film of Bio-PET Film Growth Driving Factor Analysis 
6.3.4 Laminating Film of Bio-PET Film Growth Driving Factor Analysis

7 Global 2012-2017E Bio-PET Film Segment Market Analysis (by Application) 
7.1 Global 2012-2017E Bio-PET Film Consumption by Application 
7.2 Different Application of Bio-PET Film Product Interview Price Analysis 
7.3 Different Application of Bio-PET Film Product Driving Factors Analysis 
7.3.1 Packaging of Bio-PET Film Growth Driving Factor Analysis 
7.3.2 Industrial & Specialties of Bio-PET Film Growth Driving Factor Analysis 
7.3.3 Electrical of Bio-PET Film Growth Driving Factor Analysis 
7.3.4 Imaging of Bio-PET Film Growth Driving Factor Analysis

Continuous…

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2848635

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

The Mars Generation Announces Winners of the 24 Under 24 Leaders and Innovators in STEAM and Space Awards 2018

2018 Winner 24 Under 24 Leaders and Innovators in STEAM and Space

2018 Winner 24 Under 24 Leaders and Innovators in STEAM and Space

2018 Winner 24 Under 24 Leaders and Innovators in STEAM and Space

While these students all have a passion for STEAM and/or space, it is their ability to set their passion in motion at such a young age that has earned them a place in our 2018 class.”

— Abigail Harrison

MINNEAPOLIS, MINNESOTA, UNITED STATES, January 31, 2018 /EINPresswire.com/ — Around the world, young people are accomplishing amazing things in the fields of science, technology, engineering, arts, and math (STEAM). The Mars Generation is proud to announce its first 24 Under 24 Leaders and Innovators in STEAM and Space Awards winners.

“The young individuals recognized with the 24 Under 24 have demonstrated innovation and tenacity that will drive us toward a brighter future in scientific enterprise,” said Abigail Harrison, founder of The Mars Generation (TMG).

“We are honored to be joined by our esteemed sponsors Aerojet Rocketdyne and United Launch Alliance (ULA) in presenting the 2018 awards,” said Harrison. She said having two leaders in the industry play an important role in announcing the award was a testimony to the companies’ commitment to advancing STEAM.

“We are glad to partner with The Mars Generation for these awards,” said Tory Bruno, CEO of United Launch Alliance and TMG Advisory Board member. “Together, we continue to foster enthusiastic young minds. Sponsoring the next generation of space explorers and youth interested in STEAM benefits nearly every industry.”

The number of submissions for a first-time award was impressive, explained Harrison. Having sponsors like Aerojet Rocketdyne and ULA elevated the visibility for nominations.

Julie VanKleeck, Vice President of Advanced Space and Launch Programs and Strategy at Aerojet Rocketdyne and also a TMG Advisory Board member, said the company was excited to support the 24 Under 24 Awards: “As we work on projects that enhance our understanding of space, it’s important to inspire the upcoming generation to go even further.”

“While these students all have a passion for STEAM and/or space, it is their ability to set their passion in motion at such a young age that has earned them a place in our 2018 class,” said Harrison.

The 2018 winners of the 24 Under 24 Leaders and Innovators in STEAM and Space Awards:

To learn more about the accomplishments of each winner please click here.

1. Canda Atalay, 18 (Turkey)
2. Deepack Atyam, 24 (United States)
3. Rebecca Baron, 17 (Canada)
4. Darren Charrier, 21 (Canada)
5. Joaquin Cortacans, 17 (Uruguay)
6. Bethany Downer, 23 (Canada)
7. Paoloa Figueroa-Delgado, 22 (Puerto Rico)
8. Jacqueline Grundfast, 17 (United States)
9. Pranvera Hyseni, 22 (Kosovo)
10. Roger Lascorz, 24 (Catalonia)
11. Kaitlyn Ludlam, 15 (United States)
12. Tessa McEvoy, 17 (United States)
13. Katherine McKinney, 17 (United States)
14. Maanasa Mendu, 13 (United States)
15. Collin Mitchell, 18 (United States)
16. Temidayo Oniosun, 22 (Nigeria)
17. Mylena Peixoto, 17 (Brazil)
18. Olivia Scharfman, 20 (United States)
19. Julie Sage, 13 (United States)
20. Krittanon Pond Sirorattanakul, 22 (Thailand)
21. Lisa Stojanovski, 24 (Australia)
22. Shi Tuck, 19 (United States)
23. Allie Weber, 12 (United States)
24. Melissa Vasquez-Hornik, 24 (United States)

About The Mars Generation
The Mars Generation is a volunteer-driven 501(c)(3) nonprofit with an advisory board that includes astronauts, engineers, scientists and professionals from the nonprofit and business communities. With an estimated reach of more than 25 million people since 2015 and a social media following of more than 1.1 million people the organization has served more than 10,200 students and adults from around the world through multiple programs including the Student Space Ambassador Program, Future of Space Outreach Program and Space Camp Scholarship Program. TMG is supported by over 450 donors, 1,100 members, and leading space industry sponsors. Through an innovative approach of leveraging new media technology and providing engaging content and programs the organization aims to excite and educate students and adults about the importance of human space exploration and STEAM education to the future of humankind.

About Aerojet Rocketdyne
Aerojet Rocketdyne is an innovative company delivering solutions that create value for its customers in the aerospace and defense markets. The company is a world-recognized aerospace and defense leader that provides propulsion and energetics to the space, missile defense and strategic systems, tactical systems and armaments areas, in support of domestic and international markets. Additional information about Aerojet Rocketdyne can be obtained by visiting www.Rocket.com and www.AerojetRocketdyne.com.

About United Launch Alliance
With more than a century of combined heritage, United Launch Alliance is the nation’s most experienced and reliable launch service provider. ULA has successfully delivered more than 120 satellites to orbit that aid meteorologists in tracking severe weather, unlock the mysteries of our solar system, provide critical capabilities for troops in the field and enable personal device-based GPS navigation.

Yvonne Hundshamer
The Mars Generation
612-670-0337
email us here


Source: EIN Presswire

Global Health Improvement Targets Announced On World Aspergillosis Day February 1st 2018

Prof. David Denning GAFFI President

Nothing less than a concerted international effort is required to address huge disparities in aspergillosis frequency”

— Professor David Denning

LISBON, LISBON, PORTUGAL, January 31, 2018 /EINPresswire.com/ — Aspergillosis, lung and sinus disease caused by the fungus Aspergillus, affects around 15 million people and kills over 1 million each year. Announced today at the 8th biennial Advances against Aspergillosis international conference in Lisbon starting on February 1st, are the 5 aspirational targets for aspergillosis to be achieved by 2030:

1. Survival in invasive aspergillosis increased to 90% (up from under 50%)
2. Plugging the major gaps in our understanding of the biological, immunological and genetic basis of aspergillosis
3. Diagnostics (most countries, including all of Africa have no diagnostic capability at all)
• New widely available, standardized and clinically validated diagnostics techniques
• New simple screening tests developed
4. Treatment
• New antifungal agents licensed for invasive, chronic and allergic aspergillosis and for all age groups (only 3 classes currently available)
5. At least one vaccine against aspergillosis in clinical trials or approved (none currently).

At the conference opening session, Professor David Denning, President of the Global Action Fund for Fungal Diseases (GAFFI) and Professor of Infectious Diseases in Global Health at the University of Manchester spoke on behalf of patients, doctors and researchers in calling for radical improvements. Because diagnostics are not available in so many countries, hundreds of thousands of people unknowingly die or are disabled by aspergillosis yet could be saved or cured. He said: “I have been looking after patients with aspergillosis for over 35 years, and yet we still lose patients and see too many people severely affected by this common fungus. I contributed to many clinical studies bringing the first effective oral drugs to patients (itraconazole and voriconazole), and yet the burden and deaths remains huge. Nothing less than a concerted international effort is required to address huge disparities in aspergillosis frequency.”

2018 marks the 20th anniversary of The Aspergillus Website, which the Fungal Infection Trust has been supporting. It provides a truly encyclopedic resource (>100,000 pages) and news feed to the world at no cost to the user, thanks to its many supporters over decades. Together with its sister Website for Patients, they attract over 125.000 users per month, indicative of the need for information. In 2012, the Fungal Infection Trust launched a global educational website Life Worldwide, in English and Spanish, which is also highly utilised.

The Advances in Aspergillosis conference series, held alternate years, is the premier forum for detailed and dedicated discussion of all aspects of aspergillosis, attracting over 350 delegates from 35+ countries. Topical issues include: emergence of pan-azole and echinocandin resistance which requires unique approaches, new antifungal agents and immunotherapies for chronic and allergic aspergillosis, better molecular and low-cost strategies for diagnosis and publication of several recent clinical guidelines for clinicians offer detailed guidance.

Other major needs for health improvements in aspergillosis include:
• Improvement in the public’s awareness of fungal diseases and specifically aspergillosis
• Keeping homes free from excessive Aspergillus and other moulds related to dampness, which increases the number and severity of asthma episodes
• Stronger evidence base of antifungal therapy allergic aspergillosis to reduce the number and severity of asthma episodes, and probably asthma deaths
• Hospital environments for vulnerable patients free of Aspergillus
• Reduction in azole resistance with reduced use of azole fungicides in non-essential crops
• Prevention of a new epidemic of resistance with any new classes of antifungal used for aspergillosis by not allowing such chemical class to be used as a fungicide
• Need for better surveillance and detailed epidemiology data
• Development of immunotherapies as well as vaccines

Luisa Morlano
The Goodwork Organisation Ltd
+442087471488
email us here


Source: EIN Presswire

Solar Photovoltaic Mexico Industry 2018 Production, Segmentation, Consumption and Forecast to 2030

Solar Photovoltaic Mexico Market 2018 -Develop Market-Entry and Market Expansion Strategies

PUNE, INDIA, January 31, 2018 /EINPresswire.com/ — Summary
The report provides in depth analysis on global renewable power market and global Solar Photovoltaic (PV) market with forecasts up to 2030. The report analyzes the power market scenario in Mexico (includes conventional thermal, nuclear, large hydro and renewable energy sources) and provides future outlook with forecasts up to 2030. The research details renewable power market outlook in the country (includes hydro, small hydro, biopower and Solar Photovoltaic (PV)) and provides forecasts up to 2030. The report highlights installed capacity and power generation trends from 2006 to 2030 in Mexico Solar Photovoltaic (PV) market. A detailed coverage of renewable energy policy framework governing the market with specific policies pertaining to Solar Photovoltaic (PV) is provided in the report. The research also provides company snapshots of some of the major market participants.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2811534-solar-photovoltaic-pv-in-mexico-market-outlook-to-2030-update

Scope
The report analyses global renewable power market, global Solar Photovoltaic (PV) market, Mexico power market, Mexico renewable power market and Mexico Solar Photovoltaic (PV) market. The scope of the research includes –
– A brief introduction on global carbon emissions and global primary energy consumption.
– An overview on global renewable power market, highlighting installed capacity trends, generation trends and installed capacity split by various renewable power sources. The information is covered for the historical period 2006-2016 (unless specified) and forecast period 2017-2030.
– Renewable power sources include wind (both onshore and offshore), Solar Photovoltaic (PV), concentrated solar power (CSP), small hydro power (SHP), biomass, biogas and geothermal.
– Detailed overview of the global Solar Photovoltaic (PV) market with installed capacity and generation trends, installed capacity split by major Solar Photovoltaic (PV)power countries in 2016 and key owners information of various regions.
– Power market scenario in Mexico and provides detailed market overview, installed capacity and power generation trends by various fuel types (includes thermal conventional, nuclear, large hydro and renewable energy sources) with forecasts up to 2030.
– An overview on Mexico renewable power market, highlighting installed capacity trends (2006-2030), generation trends(2006-2030) and installed capacity split by various renewable power sources in 2016.
– Detailed overview of Mexico Solar Photovoltaic (PV) market with installed capacity and generation trends and major active and upcoming Solar Photovoltaic (PV) projects.
– Deal analysis of Mexico Solar Photovoltaic (PV) market. Deals are analyzed on the basis of mergers, acquisitions, partnership, asset finance, debt offering, equity offering, private equity (PE) and venture capitalists (VC).
– Key policies and regulatory framework supporting the development of renewable power sources in general and Solar Photovoltaic (PV) in particular.
– Company snapshots of some of the major market participants in the country.

Reasons to buy
– The report will enhance your decision making capability in a more rapid and time sensitive manner.
– Identify key growth and investment opportunities in Mexico Solar Photovoltaic (PV) market.
– Facilitate decision-making based on strong historic and forecast data for Solar Photovoltaic (PV) market.
– Position yourself to gain the maximum advantage of the industry’s growth potential.
– Develop strategies based on the latest regulatory events.
– Identify key partners and business development avenues.
– Understand and respond to your competitors’ business structure, strategy and prospects.

Table of Content: Key Points
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Executive Summary 7
2.1 Global Carbon Emissions to Increase at a Lower rate During the Forecast Period 7
2.2 Technological Advancements and Government Support Driving Global Renewable Power Installations 7
2.3 Thermal Power is the Dominant Source in the Power Mix in Mexico 7
2.4 Target to Increase the Share of Clean Power to 35% in the Country’s Power Mix by 2024 9
3 Introduction 10
4 Renewable Power Market, Global, 2006-2030 16
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2811534-solar-photovoltaic-pv-in-mexico-market-outlook-to-2030-update

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Bacterial Vaginosis Drugs and Companies Pipeline Review H1 2018

Bacterial Vaginosis Assessment and Therapeutics Pipeline Review H1 2018

PUNE, INDIA, January 31, 2018 /EINPresswire.com/ — Summary
Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Bacterial Vaginosis – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2841820-bacterial-vaginosis-pipeline-review-h1-2018

The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Bacterial Vaginosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Vaginosis (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Bacterial Vaginosis – Overview
Bacterial Vaginosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bacterial Vaginosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bacterial Vaginosis – Companies Involved in Therapeutics Development
Evofem Inc
Osel Inc
Pharmiva AB
Profarma
Starpharma Holdings Ltd
Bacterial Vaginosis – Drug Profiles
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2841820-bacterial-vaginosis-pipeline-review-h1-2018

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Warts Pharmaceutical and Healthcare Analysis Information

Warts Assessment and Therapeutics Pipeline Review H1 2018

PUNE, INDIA, January 31, 2018 /EINPresswire.com/ — Summary
Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2841819-warts-pipeline-review-h1-2018

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Warts – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 16, 2, 5, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Warts – Overview
Warts – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Warts – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Warts – Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Agilvax Inc
Aviragen Therapeutics Inc
BioMAS Ltd
Cadila Healthcare Ltd
Cutanea Life Sciences Inc
Cytovation AS
G&E Herbal Biotechnology Co Ltd
Genetic Immunity Inc
Laboratories Ojer Pharma SL
LEO Pharma A/S
Nielsen Biosciences Inc
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2841819-warts-pipeline-review-h1-2018

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Community Acquired Pneumonia Drugs and Companies Pipeline Review H1 2018

Community Acquired Pneumonia Pharmaceutical and Healthcare Pipeline Review H1

PUNE, INDIA, January 31, 2018 /EINPresswire.com/ — Summary
Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Community Acquired Pneumonia – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2841816-community-acquired-pneumonia-pipeline-review-h1-2018

The Community Acquired Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 2, 6, 2, 2 and 1 respectively.

Community Acquired Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Community Acquired Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Community Acquired Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Community Acquired Pneumonia (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Community Acquired Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Community Acquired Pneumonia – Overview
Community Acquired Pneumonia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Community Acquired Pneumonia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Community Acquired Pneumonia – Companies Involved in Therapeutics Development
Biotest AG
InflaRx NV
ioGenetics Inc
Kyorin Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
Nabriva Therapeutics plc
Paratek Pharmaceuticals Inc
ProThera Biologics Inc
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2841816-community-acquired-pneumonia-pipeline-review-h1-2018

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire